Tarsons Products Q2 FY26 results: standalone PAT drops sharply YoY

Results View source PDF Explain this filing

TARSONS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.4%Reaction day

₹265.00

prior close

₹265.40

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.9%-4.3% vs market

Medical Equipment & Supplies peers, median of 14sector-0.9%-2.4% vs sector

On the reaction day the stock moved 4.3 pts less than Nifty Microcap 250 and 2.4 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

-0.7

15m

-0.4

30m

-1.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.4+0.9-4.3-0.9-2.4

Next day

-9.6+0.8-10.5-2.5-7.1

-9.4+0.7-10.2-2.7-6.7

-13.6+1.3-14.9-4.3-9.3

-13.2+0.5-13.7-5.1-8.1

-15.5+0.4-15.8-5.1-10.4

-18.2-1.5-16.7-6.4-11.9

15d

-12.3-2.4-9.9-3.9-8.4

-14.0-4.4-9.6-2.2-11.8

-15.1-7.2-7.9-13.9-1.2

-24.3-5.0-19.4-30.0+5.6

UpDownMarket · Nifty Microcap 250Sector · Medical Equipment & Supplies peers, median of 14Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

A Board meeting on November 12, 2025 approved Q2 and H1 FY26 unaudited results. Standalone revenue rose modestly to 805.08 million rupees (Q2) and 1,517.87 million rupees (H1). Standalone PAT dropped sharply to 65.27 million (Q2) and 100.97 million (H1) from 120.28 and 193.89 a year ago, hit by higher depreciation and finance costs. Price Waterhouse issued an unmodified limited review. Operating cash flow stayed positive at 404.72 million rupees (H1).

Likely market impact

Standalone PAT fell about 46 percent YoY in Q2 despite modest revenue growth, pointing to margin compression. Watch consolidated picture and guidance.